Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-guided therapy for aggressive non-Hodgkin lymphoma
2006-001641-33Phase 4Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Time to treatment failure from randomisation. Started Apr 2007; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2006-001641-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001641-33.